Company Overview and News

 
Manafort and Cohen weren't the only Trump World developments this week

2018-08-22 cnbc
Paul Manafort's and Michael Cohen's courtroom bombshells may have saturated the airwaves this week, but there were many other updates in the various legal fights swirling around President Donald Trump.
IIL INNMF

136
Sizing Up the Prospects for Roku and Yelp - Barron's

2018-08-14 barrons - 1
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
IIL TRBNW RAD SBGI TRCO INNMF TRBAB

18
What exactly is insider trading—and how do you avoid it? - MarketWatch

2018-08-13 marketwatch
The recent arrest of Rep. Christopher Collins for alleged insider trading can teach traders a few key lessons: If you come across juicy non-public information about a listed company, don’t trade on it.
BGX BGLF BX BGB IIL MS MSO INNMF

 
Chris Collins touted business success before insider trading charges

2018-08-11 cnbc
From the beginning, Chris Collins' career in politics was defined by his credentials as a rich businessman.
IIL INNMF

 
US congressman charged with insider trading ends re-election bid

2018-08-11 yahoo
Washington (AFP) - A Republican congressman who was indicted on securities fraud charges reversed course Saturday and said he will end his re-election campaign.
IIL INNMF

 
Christopher Collins, et al., Lauren Zarksy, Dorothy Zarsky (Release No. LR-24231; Aug. 10, 2018)

2018-08-10 sec.gov
The Securities and Exchange Commission filed insider trading charges on August 8, 2018, against Congressman Christopher Collins, the U.S. Representative for New York’s 27th Congressional District, his son, Cameron Collins, and a third individual, Stephen Zarsky. In a parallel action, the U.S. Attorney’s Office for the Southern District of New York today announced related criminal charges.
IIL INNMF

 
Serving on corporate board while in Congress? That could end

2018-08-10 nzherald.co.nz
WASHINGTON (AP) — The indictment of Rep. Chris Collins on insider trading charges is drawing new attention to the freedom members of Congress have to serve on corporate boards or to buy and sell stock in industries they're responsible for overseeing.
IIL INNMF

 
Member of Congress, member of corporate board? It's allowed

2018-08-09 nzherald.co.nz
WASHINGTON (AP) — The indictment of Rep. Chris Collins on insider trading charges is drawing new attention to the freedom members of Congress have to serve on corporate boards or to buy and sell stock in industries they're responsible for overseeing.
IIL INNMF

 
Rep. Collins' son and son's fiancee bought more drug company stock

2018-08-09 cnbc
Rep. Chris Collins's son and his son's fiancee bought shares of an Australian biotech company just days before dumping shares after the New York Republican allegedly tipped his son off about a failed clinical drug trial in a phone call from the White House lawn, the Securities and Exchange Commission says in a complaint.
IIL INNMF

 
Chris Collins used campaign funds to pay insider trading legal bills

2018-08-09 cnbc
Rep. Chris Collins, R-N.Y., used campaign funds to pay legal bills while he faced investigation for alleged insider trading for more than a year.
IIL INNMF

 
Concerns over Trump's 'man on the Hill' links to Aussie biotech ignored

2018-08-09 theage.com.au
It was as early as February 2017 when concerns about the conduct of US President Donald Trump’s “man on the hill”, Chris Collins, were first raised with regulators, including that he had allegedly contravened Australian corporations law. But local regulators chose not to act.
IIL INNMF

 
Concerns over Trump's 'man on the Hill' links to Aussie biotech ignored

2018-08-09 smh.com.au
It was as early as February 2017 when concerns about the conduct of US President Donald Trump’s “man on the hill”, Chris Collins, were first raised with regulators, including that he had allegedly contravened Australian corporations law. But local regulators chose not to act.
IIL INNMF

 
Australian biotech firm Innate co-operating ‘fully’ with US Securities and Exchange Commission probe

2018-08-09 perthnow.com.au
THE Australian biotech firm at the centre of an insider share trading scandal involving a US congressman says it has co-operated fully with American investigators.
IIL INNMF

 
Australian biotech company Innate says not subject of Collins investigation

2018-08-09 reuters
SYDNEY, Aug 9 (Reuters) - Australian biotech group Innate Immunotherapeutics Limited said on Thursday it was not under investigation in an insider trading case involving Republican U.S. congressman Christopher Collins.
IIL INNMF

 
GOP congressman from New York charged with insider trading

2018-08-09 nzherald.co.nz
NEW YORK (AP) — Republican U.S. Rep. Christopher Collins of New York was arrested Wednesday on charges he fed inside information he gleaned from sitting on the board of a biotechnology corporation to his son, helping family and friends dodge hundreds of thousands of dollars in losses when one of the company's drugs failed in a medical trial.
IIL INNMF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...